Skip to main content
See the bias in every story
Published • loading... • Updated

Pfizer Inc details 61% tilrekimig Phase 2 response

Pfizer Inc. reported a 61% EASI-75 response on monthly tilrekimig versus 9.1% on placebo at Week 16 in a Phase 2 atopic dermatitis study.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Mugglehead Magazine broke the news in Vancouver, Canada on Thursday, October 1, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal